This company listing is no longer active
CTI BioPharma Future Growth
Future criteria checks 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CTI BioPharma.
Key information
60.0%
Earnings growth rate
61.5%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 34.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 27 Jun 2023 |
Recent future growth updates
No updates
Recent updates
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
Aug 17CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M
Aug 08CTI BioPharma: Approval Is Great, Now There's The Follow Through
Jul 19CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis
Jul 07CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
May 04CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating
Apr 11CTI BioPharma: A Speculative Buy Into The PDUFA Date
Mar 01CTI BioPharma: Long And Troubled History, Finally Approaching Approval
Dec 24FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA
Jun 01CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis
May 06CTI BioPharma: Accelerated Approval Pathway Looks Attractive
Dec 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 309 | 99 | N/A | N/A | 4 |
| 12/31/2024 | 221 | 36 | N/A | N/A | 6 |
| 12/31/2023 | 117 | -39 | N/A | N/A | 4 |
| 3/31/2023 | 76 | -69 | -82 | -82 | N/A |
| 12/31/2022 | 54 | -93 | -81 | -81 | N/A |
| 9/30/2022 | 33 | -112 | -96 | -96 | N/A |
| 6/30/2022 | 15 | -121 | -101 | -101 | N/A |
| 3/31/2022 | 2 | -118 | -98 | -98 | N/A |
| 12/31/2021 | N/A | -98 | -85 | -85 | N/A |
| 9/30/2021 | N/A | -76 | -66 | -66 | N/A |
| 6/30/2021 | N/A | -63 | -57 | -57 | N/A |
| 3/31/2021 | N/A | -58 | -49 | -49 | N/A |
| 12/31/2020 | N/A | -52 | -42 | -42 | N/A |
| 9/30/2020 | N/A | -46 | -43 | -43 | N/A |
| 6/30/2020 | 2 | -44 | -37 | -37 | N/A |
| 3/31/2020 | 3 | -41 | -35 | -35 | N/A |
| 12/31/2019 | 3 | -40 | -28 | -28 | N/A |
| 9/30/2019 | 17 | -31 | -29 | -29 | N/A |
| 6/30/2019 | 16 | -36 | -35 | -35 | N/A |
| 3/31/2019 | 16 | -36 | -41 | -41 | N/A |
| 12/31/2018 | 26 | -29 | -40 | -40 | N/A |
| 9/30/2018 | 13 | -45 | -38 | -38 | N/A |
| 6/30/2018 | 14 | -42 | -46 | -46 | N/A |
| 3/31/2018 | 35 | -29 | -33 | -33 | N/A |
| 12/31/2017 | 25 | -45 | -39 | -39 | N/A |
| 9/30/2017 | 34 | -37 | -43 | -43 | N/A |
| 6/30/2017 | 37 | -54 | -36 | -36 | N/A |
| 3/31/2017 | 22 | -75 | -62 | -62 | N/A |
| 12/31/2016 | 57 | -52 | N/A | -77 | N/A |
| 9/30/2016 | 60 | -74 | N/A | -84 | N/A |
| 6/30/2016 | 56 | -78 | N/A | -95 | N/A |
| 3/31/2016 | 50 | -91 | N/A | -94 | N/A |
| 12/31/2015 | 16 | -123 | N/A | -95 | N/A |
| 9/30/2015 | 23 | -138 | N/A | -69 | N/A |
| 6/30/2015 | 61 | -101 | N/A | -50 | N/A |
| 3/31/2015 | 61 | -96 | N/A | -43 | N/A |
| 12/31/2014 | 60 | -96 | N/A | -40 | N/A |
| 9/30/2014 | 75 | -42 | N/A | -33 | N/A |
| 6/30/2014 | 36 | -69 | N/A | -44 | N/A |
| 3/31/2014 | 35 | -59 | N/A | -41 | N/A |
| 12/31/2013 | 35 | -50 | N/A | -36 | N/A |
| 9/30/2013 | 2 | -79 | N/A | -63 | N/A |
| 6/30/2013 | 1 | -77 | N/A | -60 | N/A |
| 3/31/2013 | 1 | -117 | N/A | -59 | N/A |
| 12/31/2012 | N/A | -115 | N/A | -63 | N/A |
| 9/30/2012 | N/A | -114 | N/A | -51 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTIC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: CTIC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CTIC is expected to become profitable in the next 3 years.
Revenue vs Market: CTIC's revenue (34% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: CTIC's revenue (34% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTIC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/28 17:13 |
| End of Day Share Price | 2023/06/23 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CTI BioPharma Corp. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fabrizio Spagna | Axia Financial Research |
| Leah Rush Cann | Brookline Capital Markets |
| null null | BTIG |